Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical research benefits go viral via Twitter.

Nursing times·2015
Same author

Ethics in research: practice and respect.

Nursing times·2014
Same author

Reality and revisionism: new evidence for Andrew C Ivy's claim to authorship of the Nuremberg Code.

Journal of the Royal Society of Medicine·2014
Same author

Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study.

PloS one·2013
Same author

Implementing a centralised pharmacovigilance service in a non-commercial setting in the United Kingdom.

Trials·2013
Same author

Lipid metabolism.

Current opinion in lipidology·2012
Same journal

Breast cancer and coronary artery disease: insights from a national inpatient sample analysis.

Future cardiology·2026
Same journal

Mitral valve dysplasia associated with left ventricular non-compaction cardiomyopathy and papillary muscle hypertrophy: a case report.

Future cardiology·2026
Same journal

Cardio-oncology awareness: a multidisciplinary survey among trainees and practicing professionals at multidisciplinary settings.

Future cardiology·2026
Same journal

Wearable devices for atrial fibrillation: diagnostic and screening roles of ECG and PPG-A systematic review.

Future cardiology·2026
Same journal

Impact of comorbid mental disorders on in‑hospital mortality and complications after ST‑segment elevation myocardial infarction.

Future cardiology·2026
Same journal

Endovascular revascularisation of lower-extremity peripheral arterial disease: technical and clinical outcomes in a Vietnamese single-center prospective cohort study.

Future cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Rosuvastatin: achieving cholesterol targets.

Allan Gaw1

  • 1Clinical Trials Unit, 4th Floor, Walton Building, Glasgow Royal Infirmary,Glasgow, G4 0SF, UK. allan.gaw@ctunit.co.uk

Future Cardiology
|October 7, 2009
PubMed
Summary
This summary is machine-generated.

Rosuvastatin is a highly effective statin for cardiovascular disease prevention, significantly lowering LDL cholesterol and raising HDL cholesterol. It demonstrates a comparable safety profile to other statins, with ongoing trials evaluating its long-term impact.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Jun 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease prevention relies on effective lipid-lowering drugs.
  • Cholesterol management is crucial for reducing cardiovascular risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of rosuvastatin in cholesterol management.
  • To assess rosuvastatin's role in achieving lipid targets for cardiovascular disease prevention.

Main Methods:

  • Review of rosuvastatin's pharmacological profile.
  • Comparison of rosuvastatin's effects on LDL-cholesterol, HDL-cholesterol, and triglycerides with other statins.
  • Assessment of rosuvastatin's safety profile regarding liver, muscle, and kidney toxicity.

Main Results:

  • Rosuvastatin provides potent low-density lipoprotein (LDL)-cholesterol lowering and significant high-density lipoprotein (HDL)-cholesterol raising.
  • It is the most effective single agent for achieving US and European cholesterol goals.
  • Rosuvastatin exhibits a safety profile comparable to other statins.

Conclusions:

  • Rosuvastatin is a highly effective and well-tolerated option for cardiovascular disease prevention.
  • Its efficacy in achieving cholesterol targets surpasses other single agents.
  • Ongoing clinical trials will further elucidate its long-term benefits and safety.